CN Patent

CN113906022A — 作为a2a/a2b抑制剂的吡唑并吡啶和三唑并吡啶

Assigned to Incyte Corp · Expires 2022-01-07 · 4y expired

What this patent protects

本申请涉及式(I)化合物， 或其药学上可接受的盐，其调节腺苷受体、例如A2A和A2B亚型受体的活性，并且可用于治疗与所述腺苷受体活性相关的疾病，包括例如癌症、发炎性疾病、心血管疾病和神经退行性疾病。

USPTO Abstract

本申请涉及式(I)化合物， 或其药学上可接受的盐，其调节腺苷受体、例如A2A和A2B亚型受体的活性，并且可用于治疗与所述腺苷受体活性相关的疾病，包括例如癌症、发炎性疾病、心血管疾病和神经退行性疾病。

Drugs covered by this patent

Patent Metadata

Patent number
CN113906022A
Jurisdiction
CN
Classification
—
Expires
2022-01-07
Drug substance claim
No
Drug product claim
No
Assignee
Incyte Corp
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.